Search Result

Pathways Recommended:	Anti-infection

Results for "

SARS-CoV infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (132) AAK1 (2) Akt (2) Angiotensin-converting Enzyme (ACE) (6) Antibiotic (11) Apoptosis (10) Autophagy (20) Bacterial (8) Casein Kinase (1) CaSR (1) Cathepsin (3) CDK (2) DNA/RNA Synthesis (8) Drug Metabolite (4) EGFR (1) Endogenous Metabolite (10) Enterovirus (1) ERK (1) Fluorescent Dye (1) FXR (4) G protein-coupled Bile Acid Receptor 1 (2) Glycosidase (1) HBV (1) HCV (3) HDAC (1) Histamine Receptor (1) Histone Methyltransferase (1) HIV (29) HIV Protease (11) Influenza Virus (3) Isotope-Labeled Compounds (17) MDM-2/p53 (1) Microtubule/Tubulin (1) MMP (1) PAI-1 (1) Parasite (17) PKC (1) PROTACs (1) Proton Pump (1) Reference Standards (14) Ser/Thr Protease (9) Sirtuin (1) Toll-like Receptor (TLR) (19) VEGFR (2) Virus Protease (16)
By Research Areas:	Cancer (37) Cardiovascular Disease (4) Endocrinology (1) Infection (130) Inflammation/Immunology (14) Metabolic Disease (15) Neurological Disease (3)

By Targets:

SARS-CoV (132)

AAK1 (2)

Akt (2)

Angiotensin-converting Enzyme (ACE) (6)

Antibiotic (11)

Apoptosis (10)

Autophagy (20)

Bacterial (8)

Casein Kinase (1)

CaSR (1)

Cathepsin (3)

CDK (2)

DNA/RNA Synthesis (8)

Drug Metabolite (4)

EGFR (1)

Endogenous Metabolite (10)

Enterovirus (1)

ERK (1)

Fluorescent Dye (1)

FXR (4)

G protein-coupled Bile Acid Receptor 1 (2)

Glycosidase (1)

HBV (1)

HCV (3)

HDAC (1)

Histamine Receptor (1)

Histone Methyltransferase (1)

HIV (29)

HIV Protease (11)

Influenza Virus (3)

Isotope-Labeled Compounds (17)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

MMP (1)

PAI-1 (1)

Parasite (17)

PKC (1)

PROTACs (1)

Proton Pump (1)

Reference Standards (14)

Ser/Thr Protease (9)

Sirtuin (1)

Toll-like Receptor (TLR) (19)

VEGFR (2)

Virus Protease (16)

By Research Areas:

Cancer (37)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (130)

Inflammation/Immunology (14)

Metabolic Disease (15)

Neurological Disease (3)

147

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156651

Zevotrelvir EDP-235	SARS-CoV	Infection
Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC₅₀ ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections .

HY-129116

SSAA09E1	SARS-CoV Cathepsin	Infection
SSAA09E1 is a cathepsin L blocker (IC₅₀: 5.33 μM).SSAA09E1 inhibits stages of viral entry. SSAA09E1 can be used for SARS-CoV infection research

HY-104077

Remdesivir 190+ Cited Publications GS-5734	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-104077R

Remdesivir (Standard) GS-5734 (Standard)	Reference Standards DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (Standard) is the analytical standard of Remdesivir. This product is intended for research and analytical applications. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-171189

C-467929	SARS-CoV	Infection
C-467929 is an Nsp15 endoribonuclease inhibitor with an IC₅₀ of 8 μM. C-467929 binds to the SARS-CoV Nsp15 protein and can be utilized in infection research .

HY-104077A

Remdesivir maleate GS-5734 maleate	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir maleate, a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir maleate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-136606

SARS-CoV MPro-IN-1	SARS-CoV	Infection
SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC₅₀ of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC₅₀ of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .

HY-162604

SARS-CoV-2-IN-90	SARS-CoV	Infection
SARS-CoV-2-IN-90 (compound 3i) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .

HY-163713

SARS-CoV-2-IN-89	SARS-CoV	Infection
SARS-CoV-2-IN-89 (Compound 2) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .

HY-146381

SARS-CoV-2-IN-20	SARS-CoV	Infection
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .

HY-173575

SARS-CoV-2 3CLpro-IN-31	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC₅₀ value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-172760

CIM-834	Virus Protease SARS-CoV	Infection
CIM-834 is an orally active and selective inhibitor targeting the coronavirus membrane protein (M protein), which potently blocks viral assembly against *SARS-CoV-2* and *SARS-CoV. CIM-834 binds to the short form of the M protein (M_short) in a non-covalent manner, stabilizing M_short and preventing its conformational switch to the long form (M_long) required for virion assembly, thereby inhibiting viral particle formation. CIM-834 is promising for research of COVID-19 and other coronavirus infections* .

HY-163912

JZD-07	SARS-CoV	Infection
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of *SARS-CoV-2* infection .

HY-174373

SARS-CoV-2-IN-113	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against *SARS-CoV-2* infection with an IC₅₀ of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of *SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV*-2 .

HY-146379

SARS-CoV-2-IN-19	SARS-CoV	Infection
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .

HY-176232

BBH-4	SARS-CoV	Infection
BBH-4 is a *SARS-CoV-2* major protease (MPro) inhibitor. BBH-4 can be used in SARS-CoV-2 infection research .

HY-104077S

Remdesivir-d5 2 Publications Verification GS-5734-d₅	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro .

HY-170767

SARS-CoV-2-IN-109	SARS-CoV	Infection
SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting *SARS-CoV* with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC₅₀=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC₅₀=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .

HY-161261

SARS-CoV-2-IN-81	AAK1 SARS-CoV	Infection
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC₅₀ value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against *SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection* .

HY-175029

ALG-097558	SARS-CoV Virus Protease	Infection
ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various *SARS-CoV-2* variants as well as other human coronaviruses (HCoVs) such as *SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC₅₀s* of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].

HY-157305

Jun11165	SARS-CoV	Infection
Jun11165 is a SARS-CoV-2 PL ^pro inhibitor (IC₅₀ ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC₅₀ value of ≤ 6 μM. Jun11165 can be used in the research of viral infections .

HY-175461

AVI-4206	SARS-CoV	Infection
AVI-4206 is a selective Mac1 inhibitor with an lC₅₀ of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of *SARS-CoV-2* infection. AVI-4206 can be used the study of *SARS-CoV-2* infection .

HY-138102

SSAA09E3	SARS-CoV	Infection
SSAA09E3 is a *SARS-CoV* entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC₅₀ of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC₅₀ of 0.15 μM .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-175344

TMP1	SARS-CoV Virus Protease Ser/Thr Protease	Infection Inflammation/Immunology
TMP1 is an orally active bispecific inhibitor of M pro (IC₅₀ = 312.5 nM)/TMPRSS2 (IC₅₀ = 1.28 μM, K_D = 10.10 μM). TMP1 exhibits broad protection against different *SARS-CoV-2* variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, *SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection* by *SARS-CoV-2* escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research .

HY-168916

Jun13296	SARS-CoV Virus Protease
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13 µM, K_i = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .

HY-174251

(±)-Tuaimenal A	SARS-CoV Virus Protease	Infection
(±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol (HY-N1417). (±)-Tuaimenal A has potent inhibitory activity against SARS-CoV-2 3CLpro with an IC₅₀ of 33.3  μM. (±)-Tuaimenal A can be used for SARS-CoV-2 infection research .

HY-174233

PROTAC SARS-CoV-2 Degrader-1	PROTACs SARS-CoV Virus Protease	Infection
PROTAC SARS-CoV-2 Degrader-1 (Compound LLP019) is a SARS-CoV-2 M ^Pro PROTAC degrader with a DC₅₀ value of 4.7 μM. PROTAC SARS-CoV-2 Degrader-1 induces M ^Pro ubiquitination and proteasomal degradation to inhibit SARS-CoV-2 replication. PROTAC SARS-CoV-2 Degrader-1 is promising for research of COVID-19 and related coronavirus infections. (Pink: DH03 (HY-32717); Black: linker (HY-42149); Blue: Thalidomide-4-O-CH2-COO(t-Bu) (HY-42771) .

HY-P990816

Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Bacterial Antibiotic	Infection
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Antibiotic HIV SARS-CoV	Infection
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-153228

Pomotrelvir 1 Publications Verification PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-168441

NCGC00537446	SARS-CoV	Infection
NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of *SARS-CoV-2. It effectively blocks the infection* and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-169092

PF-07957472	SARS-CoV Virus Protease	Infection
PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC₅₀ = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model .

HY-145949

Remdesivir de(ethylbutyl 2-aminopropanoate)	Drug Metabolite	Infection
Remdesivir de(ethylbutyl 2-aminopropanoate) is an impurity of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, has EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-90001

Ritonavir 25+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 M ^pro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of *SARS-CoV-2* and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-104077S1

Remdesivir-d4 GS-5734-d₄	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-174439

Nsp12-IN-2	SARS-CoV Virus Protease Drug Metabolite	Infection
Nsp12-IN-2 (Compound 8), the triphosphate metabolite of 4'-thiouridine (HY-W113081), is a SARS-CoV-2 Nsp12 inhibitor. Nsp12-IN-2 inhibits the RNA-dependent RNA polymerase (RdRp) activity of the SARS-CoV-2 Nsp12-Nsp7-Nsp8 complex, terminates RNA synthesis and also blocks the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 is promising for research of infections caused by SARS-CoV-2, other coronaviruses, and other RNA viruses .

HY-156597

Arbemnifosbuvir AT-752 free base	SARS-CoV	Infection
Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .

HY-104077S2

Remdesivir impurity 9-d4	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-162484

GZNL-P36	SARS-CoV Virus Protease	Infection
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^pro), with an IC₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C_max of 549 ng/mL, a half-life T_1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .

Cat. No.	Product Name

HY-L002

Anti-Infection Compound Library

3,629 compounds

An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents.

MCE provides a unique collection of 3,629 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

HY-L027

Antiviral Compound Library

1,443 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1,443 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-P11032

Mp-4D7-pF2	SARS-CoV Virus Protease	Infection
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC₅₀ of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .

HY-P2296

Abz-FRLKGGAPIKGV-EDDNP TFA	Fluorescent Dye	Others
Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .

HY-P10975

P9R	SARS-CoV Influenza Virus Enterovirus	Infection
P9R is an antiviral peptide. P9R has broad-spectrum antiviral activities against the coronaviruses (SARS-CoV-2, MERS-CoV and *SARS-CoV), A(H1N1)pdm09, A(H7N9) virus, and rhinovirus. P9R directly binds to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from A(H1N1)pdm09 infection* without generating drug-resistant virus. P9R can be used for pH-dependent respiratory viruses research .

Cat. No.	Product Name	Target	Research Area

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P990816

Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P991491

VIR-7229	SARS-CoV Influenza Virus	Infection
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Infection Structural Classification Microorganisms Source classification Polyphenols Disease Research Fields	Bacterial Antibiotic
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-N3389

Licoisoflavone A 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on *SARS-CoV-2* infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-N10109A

Gallinamide A TFA	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Parasite Cathepsin
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-134222A

N-Acetylserine N-Acetyl-L-serine	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-126419

Kobophenol A	Infection Classification of Application Fields Source classification Cyperaceae Phenols Polyphenols Plants Disease Research Fields Carex kobomugi Ohwi	SARS-CoV PKC
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC₅₀ of 1.81 μM and inhibits *SARS-CoV-2* viral infection in cells with an EC₅₀ of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC₅₀ of 52 µM .

HY-110066

(Z)-Guggulsterone 5+ Cited Publications	Structural Classification Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and *SARS-CoV-2* infection .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Structural Classification Source classification Phenols Polyphenols Endogenous metabolite	Antibiotic HIV SARS-CoV
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-W399297R

Isodeoxycholic acid (Standard) 7α,12α-Dihydroxycholanoic acid (Standard)	Structural Classification Source classification Endogenous metabolite Steroids	Endogenous Metabolite Reference Standards
Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-134222AR

N-Acetylserine (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
N-Acetylserine (Standard) is the analytical standard of N-Acetylserine (HY-134222A). This product is intended for research and analytical applications. N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-N14351

Ferrocin A	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Bacterial Antibiotic
Ferrocin A is a lipopeptide compound that targets the *SARS-CoV-2* RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections .

HY-110066R

(Z)-Guggulsterone (Standard)	Structural Classification Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Steroids	Reference Standards Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-B1513

α-Cyclodextrin 2 Publications Verification	Structural Classification Zea mays L. Polysaccharides Classification of Application Fields Gramineae Source classification Other Diseases Plants Disease Research Fields Saccharides	Microtubule/Tubulin SARS-CoV
α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against *SARS-CoV-2* infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 18 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Structural Classification Human Gut Microbiota Metabolites Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing *SARS-CoV-2* infection. Orally active .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Source classification Disease markers Endogenous metabolite Steroids	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-W012531

2-Hydroxycinnamic acid	Infection Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae Disease Research Fields	HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of *HIV/SARS-CoV* S pseudovirus with an IC₅₀** of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-W012531R

2-Hydroxycinnamic acid (Standard)	Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae	Reference Standards HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid (Standard) is the analytical standard of 2-Hydroxycinnamic acid. This product is intended for research and analytical applications. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of *HIV/SARS-CoV* S pseudovirus with an IC₅₀** of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-B1624A

Debrisoquin hemisulfate Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Endogenous metabolite Isoquinoline Alkaloids Disease Research Fields	Endogenous Metabolite
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin hemisulfate can be used for antiviral research .

Cat. No.	Product Name	Chemical Structure

HY-104077S

Remdesivir-d5 2 Publications Verification
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro .

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-W653853

Ritonavir-13C3
Ritonavir- ¹³C₃ is ¹³C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM .

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-90001S2

Ritonavir-d8
Ritonavir-d₈ is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.09 μM .

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-W707562

FOY 251-d4
FOY 251-d₄ is the deuterium labeled FOY 251 (HY-19727A). FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-17430S2

Amprenavir-13C6
Amprenavir- ¹³C₆ (VX-478- ¹³C₆) is ¹³C labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.09 μM.

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC₅₀ of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆) is the deuterium labeled rel-Ritonavir. rel-Ritonavir is a relative configuration of Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to study of HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-134222AS

N-Acetylserine-d3
N-Acetylserine-d₃ is the deuterium labeled N-Acetylserine (HY-134222A). N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-W777545

4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4
4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d₄ is the deuterium labeled Hydroxychloroquine Impurity E (HY-131262). Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-W012531S2

2-Hydroxycinnamic acid-d4

2-Hydroxycinnamic acid-d₄ is deuterium labeled 2-Hydroxycinnamic acid. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

Cat. No.	Product Name		Classification